NeuroPace (NASDAQ:NPCE) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS

NeuroPace (NASDAQ:NPCE) issued its earnings results on Tuesday. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.09, Zacks reports. NeuroPace had a negative net margin of 29.29% and a negative return on equity of 168.61%. NeuroPace updated its FY 2025 guidance to EPS.

NeuroPace Price Performance

Shares of NASDAQ:NPCE remained flat at $9.40 on Tuesday. 281,275 shares of the company’s stock were exchanged, compared to its average volume of 129,118. NeuroPace has a 52 week low of $6.27 and a 52 week high of $18.98. The business has a fifty day simple moving average of $10.12 and a 200-day simple moving average of $10.84. The company has a debt-to-equity ratio of 3.02, a quick ratio of 4.51 and a current ratio of 5.47.

Analysts Set New Price Targets

NPCE has been the subject of several analyst reports. Wells Fargo & Company cut their price target on shares of NeuroPace from $17.00 to $15.00 and set an “overweight” rating for the company in a report on Wednesday, August 13th. Zacks Research downgraded NeuroPace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroPace in a research report on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $16.60.

Institutional Trading of NeuroPace

Several hedge funds have recently made changes to their positions in NPCE. Geode Capital Management LLC lifted its position in shares of NeuroPace by 44.6% during the 2nd quarter. Geode Capital Management LLC now owns 485,162 shares of the company’s stock valued at $5,406,000 after acquiring an additional 149,595 shares during the last quarter. Legal & General Group Plc boosted its stake in NeuroPace by 86.0% in the 2nd quarter. Legal & General Group Plc now owns 2,679 shares of the company’s stock worth $30,000 after purchasing an additional 1,239 shares during the period. Rhumbline Advisers lifted its holdings in shares of NeuroPace by 114.5% in the second quarter. Rhumbline Advisers now owns 36,956 shares of the company’s stock valued at $412,000 after purchasing an additional 19,729 shares in the last quarter. Russell Investments Group Ltd. raised its position in NeuroPace by 59.1% during the second quarter. Russell Investments Group Ltd. now owns 71,463 shares of the company’s stock valued at $796,000 after buying an additional 26,547 shares during the period. Finally, Quantbot Technologies LP purchased a new position in NeuroPace during the 2nd quarter valued at about $35,000. Institutional investors own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.